Enhancing Clinical Trial Enrollment with Michel van Harten, MD

In this episode, host Shikha Jain, MD, speaks with Michel van Harten, MD, about creating better information systems for physicians and patients, how shared decision-making can improve drug development and more. •    Welcome to another exciting episode of Oncology Overdrive 0:14 •    About van Harten 0:20 •    The interview 1:00 •    What was your journey to becoming a physician and beyond to where you are now? 1:24 •    How did you learn the necessary skills to be an exceptional leader in this space?  2:51 •    How many years were you a practicing physician for? 3:53 •    What does myTomorrows do, and what drew you to this type of work? 4:54 •    Where is this service available?  7:19 •    Jain and van Harten on the challenges patients face surrounding eligibility for clinical trials.  8:36 •    Where do you see this going down the line?  10:05 •    Has your company looked into how to these services can impact diversifying clinical trial enrollment?  12:04 •    What are some challenges your company has faced?  13:50 •    How quickly do you think growth will accelerate in this space?  15:26 •    How will this work and resource have major impacts on drug development in a more accelerated way than in the past?  16:11 •    From the patient-facing side, have you faced any challenges concerning patients' willingness to be enrolled in clinical trials?  18:22 •    What is next for you, and where do you see yourself in twenty years?  19:13 •    Do you have any concerns about AI in health care? […] What should we be aware of when utilizing AI in this space?  19:45 •    Jain and van Harten on the challenges and setbacks that come from outdated and inaccurate clinical trial databases.  21:35 •    If someone could only listen to the last few minutes of this episode, what would you want listeners to take away? 23:50 •    How to contact van Harten 24:28 •    Thanks for listening 25:17 Michel van Harten, MD, is the CEO of myTomorrows. We'd love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Michel van Harten can be reached via email [email protected].  Disclosures: Jain and van Harten report no relevant financial disclosures.